Investment Landscape: Alzheimer's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Alzheimer's Disease research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 4910
Active Trials (Recruiting/Active): 1208
| Phase | Count |
|---|---|
| PHASE1 | 480 |
| PHASE1, PHASE2 | 113 |
| PHASE2 | 636 |
| PHASE2, PHASE3 | 68 |
| PHASE3 | 321 |
| PHASE4 | 168 |
| NA | 2082 |
| Not Applicable | 970 |
| Status | Count |
|---|---|
| RECRUITING | 741 |
| ACTIVE_NOT_RECRUITING | 200 |
| NOT_YET_RECRUITING | 267 |
| COMPLETED | 2529 |
| TERMINATED | 324 |
| WITHDRAWN | 107 |
Alzheimer's disease represents the largest neurodegenerative investment area with 4,910 total clinical trials. The pipeline shows 480 Phase 1, 636 Phase 2, and 321 Phase 3 trials currently active. The high number of completed trials (2529) reflects decades of research investment, though the limited Phase 3 count indicates significant attrition in later-stage development.
With 324 terminated trials historically, the field is actively exploring new modalities. Microbiome-based approaches represent an emerging area with growing trial activity. Senolytic therapies targeting cellular senescence are entering early-phase trials. Gene therapy vectors for APP and related genes are under development, though clinical translation remains challenging.
Only 6.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01